amubarvimab_plus_romlusevimab _targeted_S-gene_sequencing

As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), participants with symptomatic SARS-CoV-2 infection were given amubarvimab+romlusevimab or placebo treatment. We performed targeted Spike (S) gene next-generation sequencing to detect amubarvimab+romlusevimab resistance mutations. Using this data, we can assess whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or therapeutic efficacy in the immune-competent population.